Operating Segments

12 Months Ended

Dec. 31, 2022

Operating Segments

Operating Segments

Note 11. Operating Segments

The Company maintains two active operating segments: Specialized BioTherapeutics and Public Health Solutions. Each segment includes an element of overhead costs specifically associated with its operations, with its corporate shared services group responsible for support functions generic to both operating segments.

	For the Years Ended
	December 31,
	2022		2021
Revenues
Specialized BioTherapeutics	$	31,929	$	—
Public Health Solutions		916,982		824,268
Total	$	948,911	$	824,268
(Loss) Income from Operations
Specialized BioTherapeutics	$	(7,614,988)	$	(7,216,450)
Public Health Solutions		26,612		(542,270)
Corporate		(6,650,528)		(5,340,240)
Total	$	(14,238,904)	$	(13,098,960)
Amortization and Depreciation Expense
Specialized BioTherapeutics	$	10,087	$	7,804
Public Health Solutions		1,681		1,301
Corporate		12,794		25,056
Total	$	24,562	$	34,161
Other (Expense) Income, Net
Specialized BioTherapeutics	$	102,320	$	135,409
Corporate		(816,690)		(452,164)
Total	$	(714,370)	$	(316,755)
Share-Based Compensation
Specialized BioTherapeutics	$	138,075	$	136,594
Public Health Solutions		4,804		21,884
Corporate		190,510		203,081
Total	$	333,389	$	361,559

	As of December 31,
	2022		2021
Identifiable Assets
Specialized BioTherapeutics	$	103,742	$	128,645
Public Health Solutions		121,290		146,296
Corporate		14,054,685		26,594,986
Total	$	14,279,717	$	26,869,927